Clinical Trial Update: A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab [Phase 1]

View source ↗

Summary

This is a Phase 1/Ib study of NIZ985 alone and in combination with spartalizumab, sponsored by Novartis, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• NIZ985
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED